Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer
Conditions
Interventions
vidutolimod
cemiplimab
Locations
24
United States
University of Alabama
Birmingham, Alabama, United States
City of Hope
Duarte, California, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
University of California
Los Angeles, California, United States
GenesisCare USA
Jacksonville, Florida, United States
Orlando Health Cancer Institute
Orlando, Florida, United States
Start Date
November 30, 2021
Primary Completion Date
October 31, 2024
Completion Date
October 31, 2024
Last Updated
December 5, 2025
NCT03050268
NCT06532279
NCT05969860
NCT05695222
NCT05651828
NCT06151236
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions